National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 51 of 66
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
NCT00062244
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
NCT00060307
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00062075
Markers for Early Detection of Prostate Cancer
NCT00340717
Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00052949
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00062387
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT00063934
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
NCT00062166
Studying Normal Breast Tissue and Cancer Risk
NCT00341692
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
NCT00046189
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00059787
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
NCT00058682
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
NCT00070057
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
NCT00042978
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
NCT00058240
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
NCT00061932
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
NCT00060372
Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors
NCT00062127
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
NCT00058227
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
NCT00059475
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
NCT00063895
Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies
NCT00427726
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
NCT00060021
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
NCT00058305
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00055913
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00049036
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
NCT00058084
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
NCT00060112
Perifosine in Treating Patients With Recurrent Prostate Cancer
NCT00058214
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
NCT00020683
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
NCT00055237
High-Risk Breast Duct Epithelium
NCT00028340
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00058253
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
NCT00055692
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00058279
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00041080
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
NCT00049114
Imatinib Mesylate in Treating Patients With Recurrent Meningioma
NCT00045734
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
NCT00054665
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00058019
Cause of Familial Testicular Cancer
NCT00034424
Study of Health Effects of Cosmetic Breast Augmentation
NCT00342953
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
NCT00051311
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00054431
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
NCT00057863
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
NCT00055809
Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis
NCT00052962
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
NCT00054639
Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00054535
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
NCT00054483
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.